FI952328A0 - Ligander av eck-reseptorer - Google Patents

Ligander av eck-reseptorer

Info

Publication number
FI952328A0
FI952328A0 FI952328A FI952328A FI952328A0 FI 952328 A0 FI952328 A0 FI 952328A0 FI 952328 A FI952328 A FI 952328A FI 952328 A FI952328 A FI 952328A FI 952328 A0 FI952328 A0 FI 952328A0
Authority
FI
Finland
Prior art keywords
ligands
eck
disclosed
eck receptor
receptor
Prior art date
Application number
FI952328A
Other languages
English (en)
Finnish (fi)
Other versions
FI952328A (sv
Inventor
Timothy D Bartley
William J Boyle
Gary M Fox
Andrew A Welcher
Vann P Parker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI952328A0 publication Critical patent/FI952328A0/sv
Publication of FI952328A publication Critical patent/FI952328A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
FI952328A 1992-11-13 1995-05-12 Ligander av eck-reseptorer FI952328A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97770892A 1992-11-13 1992-11-13
US14561693A 1993-11-09 1993-11-09
PCT/US1993/010879 WO1994011020A1 (en) 1992-11-13 1993-11-12 Eck receptor ligands

Publications (2)

Publication Number Publication Date
FI952328A0 true FI952328A0 (sv) 1995-05-12
FI952328A FI952328A (sv) 1995-07-10

Family

ID=26843152

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952328A FI952328A (sv) 1992-11-13 1995-05-12 Ligander av eck-reseptorer

Country Status (14)

Country Link
US (2) US5650504A (sv)
EP (1) EP0597503B1 (sv)
JP (1) JPH08505765A (sv)
CN (1) CN1094446A (sv)
AT (1) ATE172246T1 (sv)
AU (1) AU685765B2 (sv)
CA (1) CA2149333C (sv)
DE (1) DE69321555T2 (sv)
DK (1) DK0597503T3 (sv)
ES (1) ES2121915T3 (sv)
FI (1) FI952328A (sv)
IL (1) IL107599A0 (sv)
NO (1) NO951861L (sv)
WO (1) WO1994011020A1 (sv)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007094A1 (en) * 1990-10-16 1992-04-30 The Regents Of The University Of Michigan Cytokine-induced marker for inflammatory response
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
AU669960B2 (en) * 1992-11-13 1996-06-27 Immunex Corporation Novel cytokine designated elk ligand
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
IL113252A0 (en) * 1994-04-04 1995-07-31 Regeneration Pharmaceuticals I Eph receptors binding ligands
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
AU716924B2 (en) * 1994-10-27 2000-03-09 Genentech Inc. AL-1 neurotrophic factor, a ligand for an EPH related tyrosine kinase receptor
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6100346A (en) * 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
PL199645B1 (pl) 1998-12-23 2008-10-31 Regeneron Pharma Kwas nukleinowy, polipeptyd fuzyjny, kompozycja, wektor, wektor ekspresyjny, układ gospodarz wektor, sposób wytwarzania polipeptydu fuzyjnego, kwas nukleinowy i sposób wytwarzania polipeptydu fuzyjnego
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
EP1820860A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US20020192711A1 (en) * 2001-04-20 2002-12-19 Nestor John J. Methods for identifying ligands of G-Protein-Coupled receptors
CA2485373A1 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US20040091486A1 (en) * 2002-05-10 2004-05-13 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220459B2 (en) 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004092343A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
EP1628992A4 (en) * 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic METHODS FOR MODULATING METASTASIS AND SKELETAL RELATED EVENTS RESULTING FROM METASTASES
EP1730196B1 (en) 2004-03-12 2010-12-22 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
KR20070034465A (ko) 2004-03-12 2007-03-28 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
ES2529451T3 (es) 2004-09-23 2015-02-20 Vasgene Therapeutics, Inc. Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
CA2595892A1 (en) 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
BRPI0815399A2 (pt) 2007-08-13 2019-09-24 Vasgene Therapeutics Inc tratamento de câncer usando anticorpos humanizados que se ligam ephb4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001052A (nl) * 1990-05-02 1991-12-02 Tno Werkwijze voor het bepalen van een specifiek ligand in een vloeibaar monster met behulp van een evanescent veld, alsook een daarvoor geschikt onderdeel van de benodigde meetinrichting.
WO1992007094A1 (en) * 1990-10-16 1992-04-30 The Regents Of The University Of Michigan Cytokine-induced marker for inflammatory response

Also Published As

Publication number Publication date
AU685765B2 (en) 1998-01-29
CA2149333A1 (en) 1994-05-26
DE69321555D1 (de) 1998-11-19
FI952328A (sv) 1995-07-10
EP0597503A3 (en) 1995-05-24
ATE172246T1 (de) 1998-10-15
US5716934A (en) 1998-02-10
US5650504A (en) 1997-07-22
NO951861D0 (no) 1995-05-11
IL107599A0 (en) 1994-02-27
WO1994011020A1 (en) 1994-05-26
DE69321555T2 (de) 1999-06-24
AU5599794A (en) 1994-06-08
CN1094446A (zh) 1994-11-02
DK0597503T3 (da) 1999-06-23
EP0597503B1 (en) 1998-10-14
CA2149333C (en) 2002-01-22
NO951861L (no) 1995-07-11
JPH08505765A (ja) 1996-06-25
ES2121915T3 (es) 1998-12-16
EP0597503A2 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
FI952328A0 (sv) Ligander av eck-reseptorer
WO1996036713A3 (en) Eck receptor ligands
Sanger The terminal peptides of insulin
Smith et al. The active form of tumor necrosis factor is a trimer.
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO903059L (no) Ligander og reseptorer omfattende nevnte ligander, fremgangsmaate for deres fremstilling og anvendelse.
DE3669731D1 (de) Verfahren zur umsetzung von sauerstoff enthaltenden verbindungen in fluessigen kohlenwasserstoffen.
ATE380038T1 (de) Radiometall-bindende peptide analoge
DK165199C (da) Aktivatorpraeparat, fremgangsmaade til kvantitativ bestemmelse af protein c under anvendelse af praeparatet, antithrombotisk laegemiddel indeholdende praeparatet og fremgangsmaade til udvinding af aktiveret protein c under anvendelse af praeparatet
DE3587888T2 (de) Mittel zum Abtrennen von Proteinen aus Blutplasma.
WO1994023030A3 (en) Methods and materials relating to the functional domains of dna binding proteins
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
Conrad et al. Characterization of the target cell receptor for IgE—I. Solubilization of IgE-receptor complexes from rat mast cells and rat basophilic leukemia cells
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DE58907880D1 (de) Verfahren zur Herstellung aminierter Diketodi(het)aryl-pyrrolopyrrole und Verwendung derselben als photoleitfähige Substanzen.
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
DE69637941D1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
DE3790139D2 (en) Antiparatypical antibodies, their use for detecting and treating auto-immune diseases
DE3889232T2 (de) Verfahren zum quantitativen Nachweis von Sauerstoff.
DE3688451D1 (de) Konjugate von vinblastin und seine derivate, verfahren zur herstellung derselben und diese konjugate enthaltende pharmazeutische zusammensetzungen.
DE3766258D1 (de) Spiegelndes produkt von goldener faerbung und verfahren zu dessen herstellung.
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
ATE91156T1 (de) Verfahren zur sequenzanalyse von dna.
DE3674802D1 (de) Verfahren zum nachweis von proteinen und viren.

Legal Events

Date Code Title Description
FD Application lapsed